Parental Consent to a Neonatal Clinical Study: The Roles of Uncertainty, Burden of Sample Collection and Societal Expectations.
Susanne Soendergaard Kappel, Gustav Riemer Jakobsen, Kija Lin Oestergaard...
https://pubmed.ncbi.nlm.nih.gov/41051016/Actively Recruiting
Led by Rigshospitalet, Denmark · Updated on 2024-11-15
20
Participants Needed
1
Research Sites
N/A
Total Duration
This research investigates the safety of transferring fecal bacteriophages and proteins from healthy full-term infants to preterm infants born between 260 and 306 weeks of gestational age. The goal is to develop a treatment to prevent necrotizing enterocolitis NEC, a severe gut disease common in neonatal intensive care units that causes significant illness and death among preterm babies. The study explores the role of gut microbiota and bacteriophages in NEC development. The trial includes three stages recruiting healthy donor infants to study their microbiota and collect fecal samples, testing safety and effects in preterm piglets, and finally administering fecal filtrate transfer FFT to preterm infants. Twenty preterm infants are randomly assigned to receive either FFT containing filtered viruses and proteins or a saline placebo via a nasogastric tube within 24 hours after birth and for the following three days. Participants are closely monitored clinically and biochemically for safety, including any serious adverse events within 14 days, and followed for three years to observe long-term effects. Outcomes measured include feeding tolerance, microbiota composition, growth parameters, stool characteristics, vital signs, and hospitalization duration. The trial aims to confirm safety and gather data to support larger future studies.
CONDITIONS
PrePhage - Faecal Bacteriophage Transfer for Enhanced Gastrointestinal Tract Maturation in Preterm Infants
G
Gustav R Jakobsen, md
L
Lise Aunsholt, md, phd
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Rigshospitalet, Denmark
Lead Sponsor
Lise Aunsholt, Neonatologist, Clinical Professor
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - Up to 24 hours after birth
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 4 days
Participants receive either fecal filtrate transfer or saline placebo administered by nasogastric tube within the first 4 days after birth.
4 treatment administrations within 4 days and clinical monitoring
Duration - Up to 1 month
Participants are closely monitored clinically and biochemically for safety and development, including evaluation of feeding tolerance and gut health.
Regular clinical monitoring during hospitalization and assessments up to 1 month
Duration - 3 years
Participants are followed for up to 3 years to evaluate potential late side-effects and monitor changes in fecal microbiome after treatment or placebo.
Periodic assessments over 3 years
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Susanne Soendergaard Kappel, Gustav Riemer Jakobsen, Kija Lin Oestergaard...
https://pubmed.ncbi.nlm.nih.gov/41051016/Rigshospitalet, Denmark
Lead Sponsor
Lise Aunsholt, Neonatologist, Clinical Professor
Collaborating Sponsor